Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2019

Open Access 01-12-2019 | Ovarian Cancer | Primary research

Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells

Authors: Jing Wang, Mingjun Zheng, Liancheng Zhu, Lu Deng, Xiao Li, Linging Gao, Caixia Wang, Huimin Wang, Juanjuan Liu, Bei Lin

Published in: Cancer Cell International | Issue 1/2019

Login to get access

Abstract

Background

Abnormal activation of the classic Wnt signaling pathway is closely related to the occurrence of epithelial cancers. B-cell lymphoma 9 (BCL9), a transcription factor, is a novel oncogene discovered in the classic Wnt pathway and promotes the occurrence and development of various tumors. Ovarian cancer is the gynecological malignant tumor with the highest mortality because it is difficult to diagnose early, and easy to relapse and metastasis. The expression and role of BCL9 in epithelial ovarian cancer (EOC) have not been studied. Thus, in this research, we aimed to investigate the expression and clinical significance of BCL9 in EOC tissues and its effect on the malignant biological behavior of human ovarian cancer cells.

Methods

We detect the expression of BCL9 in ovarian epithelial tumor tissues and normal ovarian tissues using immunohistochemistry and analyzed the relationship between it and clinicopathological parameters and patient prognosis. The expression of proteins was detected by Western blot. The MTT assay, flow cytometry, the scratch assay, and the transwell assay were used to detect cell proliferation, apoptosis, migration, and invasion, respectively. A total of 374 ovarian cancer tissue samples were collected using TCGA database. A gene set enrichment analysis of BCL9 was performed.

Results

BCL9 was overexpressed in EOC tissues. The level of BCL9 expression was correlated with the 5-year progression-free survival rate and overall survival rate in ovarian cancer patients and independently predicted the risk of ovarian cancer recurrence. Low BCL9 expression inhibited proliferation, invasion and migration of EOC cells, decreased MMP2 and MMP9 expression of ES-2 cell line, increased the BAX/BCL2 ratio and promoted apoptosis of EOC cells.

Conclusion

BCL9 is overexpressed in epithelial ovarian tumors, resulting in a poor prognosis for ovarian cancer patients. Low BCL9 expression can promote ovarian cancer cell apoptosis, inhibit proliferation and migration. BCL9 promotes the development of ovarian cancer.
Literature
1.
2.
Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Gatovsky D, Sliva ML, Dyer MJ. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood. 1998;91(6):1873–81.PubMedCrossRef
3.
Brembeck FH, Rosário M, Birchmeier W. Balancing cell adhesion and Wnt signaling, the key role of β-catenin. Curr Opin Genet Dev. 2006;16(1):51–9.PubMedCrossRef
4.
Kennedy MW, Cha SW, Tadjuidje E, Andrews PG, Heasman J, Kao KR. A co-dependent requirement of xBCL9 and Pygopus for embryonic body axis development in Xenopus. Dev Dyn. 2010;239(1):271–83.PubMed
5.
Sampietro J, Dahlberg CL, Cho US, Hinds TR, Kimelman D, Xu W. Crystal structure of a β-catenin/BCL9/TCF4 complex. Mol Cell. 2006;24(2):293–300.PubMedCrossRef
6.
Mieszczanek J, Roche M, Bienz M. A role of Pygopus as an anti-repressor in facilitating Wnt-dependent transcription. Proc Natl Acad Sci USA. 2008;105(49):19324–9.PubMedCrossRefPubMedCentral
7.
Kramps T, Peter O, Brunner E, Nellen D, Froesch B, Chatterjee S, Murone M, Züllig S, Basler K. Wnt/wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear β-catenin-TCF complex. Cell. 2002;109(1):47–60.PubMedCrossRef
8.
Kessler R, Hausmann G, Basler K. The PHD domain is required to link drosophila pygopus to legless/beta-catenin and not to histone H3. Mech Dev. 2009;126(8):752–9.PubMedCrossRef
9.
Nakamura Y, Umehara TH, Hayashizaki Y, Inoue M, Kiqawa T, Shirouzu M, Terada T, Tanaka A, Padmanabhan B, Yokoyama S. Crystal structure analysis of the PHD domain of the transcription co-activator pygopus. J Mol Biol. 2007;370(1):80–92.PubMedCrossRef
10.
Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545–50.PubMedPubMedCentralCrossRef
11.
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20(20):781–810.PubMedCrossRef
12.
Staal FJ, Clevers HC. WNT signalling and haematopoiesis: a WNT–WNT situation. Nat Rev Immunol. 2005;5(1):21–30.PubMedCrossRef
13.
Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–51.PubMed
14.
Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008;8(5):387–98.PubMedCrossRef
15.
Mosimann C, Hausmann G, Basler K. Beta-Catenin hits chromatin: regulation of Wnt target gene activation. Nat Rev Mol Cell Biol. 2009;10(4):276–86.PubMedCrossRef
16.
Cavallo RA, Cox RT, Moline MM, Roose J, Polevoy GA, Clevers H, Peifer M, Bejsovec A. Drosophila TCF and Groucho interact to repress wingless signalling activity. Nature. 1998;395(6702):604–8.PubMedCrossRef
17.
Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Disz-Griffero F, Pena-Cruz V, Bertaqnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009;69(19):7577–86.PubMedPubMedCentralCrossRef
18.
Moor AE, Pascale A, Claudio C, Rodriquez P, Wiedemann N, Baruthio F, Deka J, André S, Valenta T, Moor MB, Győrffy B, Barras D, Delorenzi M, Basler K, Aguet M. BCL9/9L-β-catenin signaling is associated with poor outcome in colorectal cancer. EBioMedicine. 2015;2(12):1932–43.PubMedPubMedCentralCrossRef
19.
Brown TC, Nicolson NG, Korah R, Carling T. BCL9 Upregulation in adrenocortical carcinoma: a novel Wnt/β-catenin activating event driving adrenocortical malignancy. J Am Coll Surg. 2018;226(6):988–95.PubMedCrossRef
20.
He G, Yang S, Chen Y, Cai C, Zhuo Y, Luo H, Cai Z, Jiang F, Ling X. Association of BCL9 expression with prostate cancer clinicopathological features and survival. Zhonghua Yi Xue Za Zhi. 2015;95(32):2603–6.PubMed
21.
22.
23.
24.
Singh D, Srivastava SK, Chaudhuri TK, Upadhyay G. Multifaceted role of matrix metalloproteinases (MMPs). Front Mol Biosci. 2015;2:19.PubMedPubMedCentral
25.
Ling XH, Chen ZY, Luo HW, Liu ZZ, Liang YK, Chen GX, Jiang FN, Zhong WD. BCL9, a coactivator for Wnt/β-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression. Oncol Lett. 2016;11(3):2001–8.PubMedPubMedCentralCrossRef
26.
Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, Tao J, Tai YT, Treon S, Pinkus G, Kuo WP, Hideshima T, Bouxsein M, Munshi N, Anderson K, Carrasco R. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res. 2014;74(6):1801–13.PubMedPubMedCentralCrossRef
27.
Wang J, Ying Y, Bo S, Li G, Yuan F. Differentially expressed microRNA-218 modulates the viability of renal cell carcinoma by regulating BCL9. Mol Med Rep. 2016;14(2):1829–34.PubMedCrossRef
28.
Yang C, Xu Y, Cheng F, Hu Y, Yang S, Rao J, Wang X. miR-1301 inhibits hepatocellular carcinoma cell migration, invasion, and angiogenesis by decreasing Wnt/β-catenin signaling through targeting BCL9. Cell Death Dis. 2017;8(8):e2999.PubMedPubMedCentralCrossRef
29.
Liu X, Ji Q, Zhang C, Liu X, Liu Y, Liu N, Sui H, Zhou L, Wang S, Li Q. miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models. Sci Rep. 2017;7(1):7113.PubMedPubMedCentralCrossRef
30.
Jia W, Eneh JO, Ratnaparkhe S, Altman MK, Murph MM. MicroRNA-30c-2* expressed in ovarian cancer cells suppresses growth factor-induced cellular proliferation and downregulates the oncogene BCL9. Mol Cancer Res. 2011;9(12):1732–45.PubMedCrossRef
31.
Kawamoto SA, Thompson AD, Coleska A, Nikolovska-Coleska Z, Yi H, Wang S. Analysis of the interaction of BCL9 with β-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for the interaction. Biochemistry. 2009;48(40):9534–41.PubMedCrossRef
32.
Fan R, He H, Yao W, Zhu Y, Zhou X, Gui M, Lu J, Xi H, Deng Z, Fan M. SOX7 suppresses Wnt signaling by disrupting β-catenin/BCL9 interaction. DNA Cell Biol. 2017;37(2):126–32.PubMedCrossRef
33.
Wisniewski JA, Yin J, Teuscher KB, Zhang M, Ji H. Structure-based design of 1,4-dibenzoylpiperazines as β-catenin/B cell lymphoma 9 protein–protein interaction inhibitors. ACS Med Chem Lett. 2016;7(5):508–13.PubMedPubMedCentralCrossRef
Metadata
Title
Low BCL9 expression inhibited ovarian epithelial malignant tumor progression by decreasing proliferation, migration, and increasing apoptosis to cancer cells
Authors
Jing Wang
Mingjun Zheng
Liancheng Zhu
Lu Deng
Xiao Li
Linging Gao
Caixia Wang
Huimin Wang
Juanjuan Liu
Bei Lin
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2019
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-019-1009-5

Other articles of this Issue 1/2019

Cancer Cell International 1/2019 Go to the issue

Primary research

Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase

Review

Why are olfactory ensheathing cell tumors so rare?

Primary research

TUFT1 promotes metastasis and chemoresistance in triple negative breast cancer through the TUFT1/Rab5/Rac1 pathway

Primary research

Novel sulphamoylated 2-methoxy estradiol derivatives inhibit breast cancer migration by disrupting microtubule turnover and organization

Primary research

KLF8 overexpression promotes the growth of human lung cancer cells by promoting the expression of JMJD2A

Primary research

The lncRNA TDRG1 promotes cell proliferation, migration and invasion by targeting miR-326 to regulate MAPK1 expression in cervical cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits